The mitochondria-targeted drug Met attenuates upregulation of the immune checkpoints programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG-3), thereby increasing CD8+ T cell infiltration and survival in the harsh tumor microenvironment (271). The gene discussed is LAG3; the disease is neoplasm.